NCT01999322View on ClinicalTrials.gov

A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 19, 2013

Primary Completion Date

May 14, 2014

Study Completion Date

May 14, 2014

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

Faster-acting insulin aspart

Administered subcutaneously (s.c., under the skin). Dose individually adjusted.

DRUG

insulin aspart

Administered subcutaneously (s.c., under the skin). Dose individually adjusted.

Trial Locations (2)

30318

Novo Nordisk Investigational Site, Atlanta

41460

Novo Nordisk Investigational Site, Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY